Title:

A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients

Creator:

Lilienfield, Lawrence S.
Partenope, Edward A.
Freis, Edward D.
Rose, John C.

Date:

April 1954

Description:

Here, Freis's team studied the effectiveness of pentapyrrolidinium (a ganglionic-blocking agent, also called pentolinium) as an antihypertensive treatment. They concluded that the drug had several advantages in the treatment of severe hypertension over another ganglionic-blocking agent, hexamethonium. The drug's attributes, longer duration of action, greater potency, and a more uniform response to oral administration, more than compensated for its side effects and the frequent need to adjust dosage.

Periodical:

Circulation

Publisher:

American Heart Association

Location:

Box: 7. Folder: 11

Rights:

Public Domain

Genre:

Articles

Subject:

Hypertension, Antihypertensive Agents, Hexamethonium, and Pentolinium Tartrate

Format:

Text

Extent:

7 pages

Language:

English

Legacy Source Citation:

Periodical. Freis, Edward D., Edward A. Partenope, Lawrence S. Lilienfield, and John C. Rose. "A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients." Circulation IX, 4 (April 1954): 540-546. Article. 7 Images.. Circulation

Legacy ID:

XFBBDB

NLM ID:

101584929X43

Profiles Collection:

The Edward D. Freis Papers

Shareable Link:

https://profiles.nlm.nih.gov/101584929X43

Story Section:

The Veterans Administration Hospital and Georgetown University School of Medicine, 1949-1964